Related Experiment Video
Updated: Jun 3, 2026

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation
Published on: February 15, 2018
Probiotics and necrotizing enterocolitis in preterm infants after the food and drug administration warning actions
Veeral N Tolia1,2, Monica M Bennett3, Darren Handler4
1Pediatrix Center for Research Education, Quality and Safety, Sunrise, FL, USA. veeraltolia@gmail.com.
Insights
Following FDA actions, probiotic use in preterm infants dropped significantly, leading to an increase in necrotizing enterocolitis (NEC) in high-use centers. Low-use centers saw no change in NEC rates.
Area of Science:
- Neonatalogy
- Gastroenterology
- Public Health
Background:
- Necrotizing enterocolitis (NEC) is a serious gastrointestinal condition affecting preterm infants.
- Probiotics are often used to prevent NEC in vulnerable neonates.
- FDA actions in 2023 prompted changes in clinical practice regarding probiotic use.
Purpose of the Study:
- To assess the impact of FDA actions on probiotic use in preterm infants.
- To evaluate the subsequent changes in necrotizing enterocolitis (NEC) incidence.
- To compare NEC rates between high and low probiotic-use centers post-FDA action.
Main Methods:
- Natural experiment observational study utilizing the Pediatrix Clinical Data Warehouse.
- Comparison of NEC incidence in high probiotic-use centers (HUCs) versus low-use centers (LUCs).
- Difference-in-differences analysis applied to data from October 2022 to March 2025.
Main Results:
- Probiotic use dramatically decreased in HUCs (86% to 6.9%) post-FDA action, with a smaller decrease in LUCs (13% to 0.1%).
- NEC incidence rose in HUCs (2.7% to 4.4%) but remained stable at 3.6% in LUCs.
- An adjusted increase in NEC was observed in HUCs compared to LUCs (1.18%; P=0.045).
Conclusions:
- Rapid cessation of probiotic use in centers with routine use was associated with increased NEC incidence.
- These findings highlight the potential impact of practice changes on neonatal outcomes.
- Further research is needed to understand the long-term implications and optimal strategies for NEC prevention.
Objective:
To evaluate changes in probiotic use and necrotizing enterocolitis (NEC) in preterm infants following the 2023 FDA actions.
Study Design:
Natural experiment observational study of preterm infants from the Pediatrix Clinical Data Warehouse comparing NEC among infants in high probiotic-use (HUC) centers versus low-use centers (LUC) using difference-in-differences analyses from October 2022-September 2023 to April 2024-March 2025.
Results:
There were 2785 infants in the HUCs and 7298 infants in the LUCs. After FDA action, probiotic use decreased in HUCs (86-6.9%); the decrease was smaller in LUCs (13-0.1%). NEC incidence increased in HUCs (2.7-4.4%), but remained unchanged in LUCs at 3.6% (adjusted difference-in-difference in NEC in HUCs compared to LUCs: 1.18%; 95% CI 0.03-2.33%, P = 0.045).
Conclusion:
NEC incidence increased in centers routinely using probiotics after rapid cessation of use following FDA actions.
Related Concept Videos
Microbiota Modulation by Antibiotics
Drugs for Treatment of Constipation-Predominant IBS
Botulism
Probiotics
Bacterial Gastroenteritis
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

